Yatharth Hospital & Trauma Care Services Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Yatharth Hospital & Trauma Care Services Ltd filed with BSE on 03 Jun 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Yatharth Hospital reported consolidated revenue of approximately INR 12,072 million for FY26, up 36% year-over-year, with EBITDA rising 30% YoY to INR 2,921 million. Management discussed the acquisition of an under-construction hospital in Sector 40, Gurugram, ramp-up progress at newly commissioned hospitals in New Delhi, Faridabad Sector 20, and Agra, and the impact of revised CGHS rates on revenue and margins. The company also addressed occupancy levels, ARPOB trends, debt position, and its target of reaching 5,000 beds within three years.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Consolidated revenue: INR 12,072 million (FY26)
p. 4
“During the year, the company reported consolidated revenue of approximately INR 12,072 million reflecting a robust growth of 36% YoY, while EBITDA increased by 30% YoY to INR 2,921 million.”
Yatharth Tyagi, page 4 of the filed PDF · View the filing
Q4 revenue: INR 3,416 million (Q4 FY26)
p. 6
“During the quarter, we reported a revenue of INR 3,416 million, reflecting a growth of 47% year-over-year and 6% quarter-overquarter.”
Pankaj Prabhakar, page 6 of the filed PDF · View the filing
Occupancy: 71% (Q4 FY26)
p. 6
“Occupancy across the network stood at 71% in Q4 FY'26, while FY '26 occupancy stood at 68%.”
Pankaj Prabhakar, page 6 of the filed PDF · View the filing
ARPOB: INR 33,282 (Q4 FY26)
p. 6
“Our ARPOB improved to INR 33,282 in Q4 FY '26, up 5% year-over-year, while FY '26 ARPOB stood at INR 33,124, up 7% year-over-year.”
Pankaj Prabhakar, page 6 of the filed PDF · View the filing
Quarterly EBITDA: INR 799 million (Q4 FY26)
p. 6
“On the profitability front, we achieved our highest ever quarterly EBITDA of INR 799 million, reflecting a growth of 37% year-over-year, with EBITDA margin at 23.4%.”
Pankaj Prabhakar, page 6 of the filed PDF · View the filing
FY26 EBITDA margin: 24.2% (FY26)
p. 6
“For FY '26, EBITDA stood at INR 2,921 million, with margins at 24.2%.”
Pankaj Prabhakar, page 6 of the filed PDF · View the filing
Adjusted EBITDA margin: 28.5% (FY26)
p. 6
“Adjusted for initial ramp-up losses at our new hospitals, adjusted EBITDA margin remains strong at 30.4% in Q4, and 28.5% for FY '26, reflecting operating leverage and improved mix.”
Pankaj Prabhakar, page 6 of the filed PDF · View the filing
Profit after tax: INR 1,703 million (FY26)
p. 6
“while FY '26 PAT stood at INR 1,703 million, reflecting a growth of 30% year-over-year.”
Pankaj Prabhakar, page 6 of the filed PDF · View the filing
Total cash position: INR 3,931 million (FY26 year-end)
p. 6
“We ended the year with a healthy total cash position of INR 3,931 million, a net cash position of INR 1,160 million, providing us with ample financial flexibility to pursue growth opportunities, while continuing investment infrastructure, technology, and clinical excellence.”
Pankaj Prabhakar, page 6 of the filed PDF · View the filing
Debt level: INR 230 crores
p. 7
“And as far as the debt levels are concerned, somewhere our debt today is at INR 230 crores.”
Yatharth Tyagi, page 7 of the filed PDF · View the filing
Net debt: INR 116 crores
p. 8
“So, going forward, yes, we will also take certain debt. But even if you look today, as far as our net debt cash position is concerned, so we stand, our net debt today stands at INR 116 crores.”
Yatharth Tyagi, page 8 of the filed PDF · View the filing
Debtor days: 112 days (FY26)
p. 12
“Yes, so as we informed earlier for FY2025 we clocked debtor days of 124 debtor days and this year that is financial 2026 we had a debtor days of 112 debtor days.”
Sonu Goyal, page 12 of the filed PDF · View the filing
Agra hospital monthly revenue run rate: approximately INR 7 crore
p. 5
“Since its integration effective February 2026, the hospital has demonstrated encouraging traction, achieving a monthly revenue run rate of approximately INR 7 crore, along with double-digit EBITDA margins, reflecting strong patient inflows and a healthy operating start.”
Yatharth Tyagi, page 5 of the filed PDF · View the filing
Oncology contribution to group revenue: 10%
p. 14
“So, if you see at a group level, oncology contributes to 10% of our overall revenue.”
Yatharth Tyagi, page 14 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Bed capacity — 5,000 beds · next three years
stated as an aspiration by Yatharth Tyagi
p. 5
“We remain confident of achieving our target of 5,000 beds over the next three years.”
Yatharth Tyagi, page 5 of the filed PDF · View the filing
EBITDA margin — 24% to 25% · FY27
stated firmly by Yatharth Tyagi
p. 11
“Our margin guidance has always been somewhere around 24% to 25%. And we have been delivering on that. And going forward also, we do not see any variation from our margin guidance is concerned.”
Yatharth Tyagi, page 11 of the filed PDF · View the filing
Revenue growth — surpass 36% YoY · FY27
stated as an aspiration by Yatharth Tyagi
p. 11
“We feel that in '27, this we would surpass this 36% YoY revenue growth.”
Yatharth Tyagi, page 11 of the filed PDF · View the filing
Debtor days — 90 to 95 days · FY27
stated as an aspiration by Sonu Goyal
p. 12
“But for FY '27 the outlook tend to around 90 to 95 days. What we are aiming for 90 to 95 days for FY2027.”
Sonu Goyal, page 12 of the filed PDF · View the filing
Government payer mix — around 25% · next two financial years
stated as an aspiration by Amit Kumar Singh
p. 13
“But as we had mentioned, previous efforts are going on to reduce it by and close it to around 25% in next probably two financial years.”
Amit Kumar Singh, page 13 of the filed PDF · View the filing
New Delhi and Faridabad Sector 20 hospitals EBITDA breakeven — EBITDA breakeven · FY27 H2
stated firmly by Yatharth Tyagi
p. 11
“So, I think both these two hospitals combined together, you will see in this FY '27 H2, that both these two hospitals would be EBITDA breakeven.”
Yatharth Tyagi, page 11 of the filed PDF · View the filing
Gurugram hospital ARPOB — upwards of INR 50,000
stated as an aspiration by Yatharth Tyagi
p. 8
“As far as Gurugram Hospital is concerned, we expect ARPOB in Gurugram to be upwards of INR 50,000.”
Yatharth Tyagi, page 8 of the filed PDF · View the filing
Gurugram hospital commencement — operational · April 2027
stated firmly by Yatharth Tyagi
p. 4
“We expect the hospital to become operational by April 2027.”
Yatharth Tyagi, page 4 of the filed PDF · View the filing
ARPOB growth — close to 10% · upcoming years
stated as an aspiration by Yatharth Tyagi
p. 8
“As far as ARPOB is concerned, going forward, also this growth should be close to 10% for upcoming years is concerned.”
Yatharth Tyagi, page 8 of the filed PDF · View the filing
Gurugram hospital breakeven — breakeven · around 15 months from operationalization
stated as an aspiration by Yatharth Tyagi
p. 15
“And, similar expectations would be to break-even would be somewhere around 15 months from the date it gets operationalized.”
Yatharth Tyagi, page 15 of the filed PDF · View the filing
Income tax matter resolution — resolved · before end of Q2 FY27
stated as an aspiration by Yatharth Tyagi
p. 17
“For the complete case of order to be out there, we feel that before the end of Quarter 2 for this financial year is somewhere when the whole matter would be resolved.”
Yatharth Tyagi, page 17 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management provided occupancy percentages and bed capacities for each new facility, noting headroom for growth.
Answered by Nitin Gupta
Asked by Ashutosh Adsare: What are the current occupancy levels and bed capacities at the new hospitals (Model Town Delhi, Faridabad Sector 20, Agra, Jhansi)?
p. 7
“We have a current occupancy level of 32% in the Model Town, that is Delhi, with the census capacity of 100 beds., with capacity of 300 beds in Delhi.”
Nitin Gupta, page 7 of the filed PDF · View the filing
Management reaffirmed margin guidance of 24-25% and expects revenue growth to surpass FY26's 36% YoY growth.
Answered by Yatharth Tyagi
Asked by Akshat Mehta: How should revenue and margins be viewed for FY27 given new acquisitions ramping up?
p. 11
“So, as far as margins are concerned, we have always maintained that at a consolidated level for the full year. Our margin guidance has always been somewhere around 24% to 25%.”
Yatharth Tyagi, page 11 of the filed PDF · View the filing
Management quantified a 5% revenue upside and over 3% EBITDA benefit from the revised CGHS rates effective December.
Answered by Sonu Goyal
Asked by Dhaval Sangoi: What was the CGHS rate benefit booked in FY26 and Q4?
p. 14
“So, there is upside of around 5% in our overall business with the revised guidelines by the government, which was come in the month of December.”
Sonu Goyal, page 14 of the filed PDF · View the filing
Management said there was a marginal impact of about 20-30% pricing impact within the oncology segment, which is 10% of group revenue, but oncology revenue growth is expected to continue.
Answered by Yatharth Tyagi
Asked by Dhaval Sangoi: Has there been an impact on oncology from chemotherapy drug price controls?
p. 14
“So, if you see at a group level, oncology contributes to 10% of our overall revenue. Now, what we have measured is certain oncology drugs that were sort of the pricing had been capped, as far as those impact is concerned within that 10% oncology revenue, we see somewhere an impact of close to 20% odd to 30% of the pricing within that 10% of oncology.”
Yatharth Tyagi, page 14 of the filed PDF · View the filing
Management acknowledged a dip across the industry over the last 3-4 months but expects improvement in coming quarters, citing efforts in the African market.
Answered by Amit Kumar Singh
Asked by Deekshant Gupta: Are international patient volumes being impacted by the West Asia crisis in Q1 FY27?
p. 14
“Yes, so it's overall, we saw that whatever had happened in the last 3-4 months, there was a dip across the industry.”
Amit Kumar Singh, page 14 of the filed PDF · View the filing
Management stated Model Town has an EBITDA loss of INR 21 crore and Faridabad new hospital INR 9 crore, while Agra was already EBITDA positive at acquisition with an 18% margin.
Answered by Nitin Gupta
Asked by Vidhi Shah: What is the current loss from new hospitals and when will Agra break even?
p. 16
“Among the entire pie at the Model Town New Delhi, so we have a EBITDA loss of INR 21 Cr. Similarly, in the Faridabad new hospital, which has started in this year having a EBITDA loss of 9 Cr.”
Nitin Gupta, page 16 of the filed PDF · View the filing
Management said the matter is at its final leg, with no major financial liability expected, and resolution anticipated before end of Q2 FY27.
Answered by Yatharth Tyagi
Asked by Satyam Kumar: What is the current status of the income tax issue?
p. 17
“Income tax issue is almost at its final leg of conclusion.”
Yatharth Tyagi, page 17 of the filed PDF · View the filing
Risks flagged
Rise in interest cost due to debt taken to fund the Agra acquisition
p. 7
“So, as we know, we have invested in Agra. So, we have taken certain loan to fund the Agra unit. That's the main reason there is an upside in the interest cost what you were asking for.”
Sonu Goyal, page 7 of the filed PDF · View the filing
Price caps on certain oncology drugs affecting a portion of oncology revenue
p. 14
“we see somewhere an impact of close to 20% odd to 30% of the pricing within that 10% of oncology.”
Yatharth Tyagi, page 14 of the filed PDF · View the filing
Dip in international patient inflows due to regional disruptions including closures in Bangladesh, Afghanistan and Middle East disruption
p. 14
“But we believe that some of the particularly for India, like Bangladesh was closed, Afghanistan was closed, Middle East has got disrupted.”
Amit Kumar Singh, page 14 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.